1
1
2
Moore’s Law
$3B
$4K
1999 20132005
Cost to
sequence
genome
Co
st
Pe
r G
en
om
eIn
form
atio
n V
alu
e
Genomic Sequencing: Unparalleled Productivity
3
San Diego is at the Heart of Genomics
4
Health Horizons Program. Institute for the Future. Top Ten Impediments to Better Health & Health Care in the United States. May 2005.
Error Rates in Healthcare Higher than Other Industries
5
• The total addressable Genomics 2.0 app market is made up of both existing markets that could adopt new technologies as well as a number of new and emerging markets
Genomics 2.0 Potentially a US$23bn TAM
6
7
8
9
Wrong drug Selected,Find out
6 months later
The Cost Of A Wrong Answer
Note: metastatic basal cell carcinoma
10
Oncology: Collision Course with Complexity
• 500+ compounds on the way
• Targeting more than 200 biomarkers
•Multiple Dx tests for each marker
11
Cancer characterization has shifted from anatomic to genomic
12
19th Century Personalized Medicine
13
20th Century Personalized Medicine
14
+ +
Changing Medicine Forever
Empiric Medicine
Evidence Based Medicine
Personalized (Sequencing)
Medicine
Real Personalized Medicine is here … TODAY
15
My Interests in the Evolving Ecosystem
Enabling Technologies
Better Diagnostics & Monitoring
Treatment Delivery Frameworks
Drug Discovery & Development
16
~$6M Saving Over 4 Yearsin Compute, Overhead, Networking & Storage costs for each HiSeq X Ten
To Analyze the Data Generated by One HiSeq X Ten
Takes Over 50 High End Compute Servers…
Or Just Accelerator Card1analyzes a whole human genome in 18 min
(A high end server takes 24 hours to do this!)
That is because…
Which provides…
17
Epic Sciences – Technical Strengths and Applications
+CK-/CD45- (EMT cells)
Traditional CTC Process
Patient Sample
EpicProcess
Epithelial CTCs
Epithelial CTCs
Apoptotic CTCs
Small CTCs
• Unbiased approach, no enrichment
• See all CTC subtypes
• Subtypes confirmed by genomics
Recurrence Detection
Therapy Monitoring
Therapy Selection
ScreeningPhase I Phase II Phase III
CLINICAL TRIALS Patient Care
• Diagnostic assays for observational trials
• Diagnostic assays for patient selection in interventional trials
• On label, marketed CDx for therapy selection
• Novel independent diagnostics for therapy selection
• Real-time monitoring for drug resistance
“No Cell Left Behind” Application Areas
18
RainTree – Creating Gold Standard Oncology Network
19
GPO / Distribution
Data(core analytics)
Care Management
Regional ACO’s
Orals, injectable, infusion
Pharmacy network
Pharma portal
Outcome analytics
Protocols
Best practices
Risk bearing
Multi-Billion Opportunity
Source: NIH Office of the Director, Office of Budget
officeofbudget.od.nih.gov
NIH Appropriations in
Current and Constant Dollars
Pivoting to translational research and
partnerships to close NIH funding gap
• Implement 10-year strategic vision to ensure financial stability
• Leverage human biology and drug discovery expertise to accelerate therapeutics discovery
• Form clinical partnerships to advance patient-oriented research
• Partner with top-tier pharma/ biotech to diversify revenue
$0
$5,000,000,000
$10,000,000,000
$15,000,000,000
$20,000,000,000
$25,000,000,000
$30,000,000,000
$35,000,000,000
19951998
20012004
20072010
2013Constant $ (1995)Current $
20
Building a Life Sciences Powerhouse
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
• 50 transaction
• 5000 patents
• $1.3 billion EBITDA
$3.96B
21
22% CAGR
$680M
A few thoughts on investing
• Look for ‘T’ Shaped Leaders
• The ‘weather’ is important, but so is the ‘climate’
• Get ahead of big ideas, but have the staying power to capture the value
• Have someone look over your shoulder to double-check your thesis
• Venture investing is full contact sport – you need to be in the huddle with the management team
22